Dark truth about secret new filler treatment that uses tissue from DEAD PEOPLE... as doctors issue urgent warning
Even Scarlett James will admit that her most recent plastic surgery sounds strange.In a last-ditch effort to achieve a more 'shapely' figure, the 31-year-old New Yorker went under the knife – and in this case, the syringe – for a new aesthetics procedure.She was injected with fat cells drawn from the body of a dead donor.'It's a little bit interesting to say the least – cadaver fat getting injected into you,' James, who works as a project manager for a real estate group, told the Daily Mail.But it was, James believed, the only solution for filling in her 'hip dips.' And nearly a year after undergoing the 'weird' procedure, she insists it has transformed her life.'It has improved my confidence. It makes me feel more womanly,' she said.Created by Tiger Biosciences, leaders in skin grafting and experts in tissue engineering, the filler, called Alloclae, has been hailed by doctors as a breakthrough in plastic surgery.Producing an injectable out of the cells of cadavers may sound macabre, but there are plenty lining up to spend tens of thousands for a jab of this 'game-changing' substance. Producing an injectable out of the cells of cadavers may sound macabre, but there are plenty lining up to spend tens of thousands for a jab of this 'game-changing' substance Producing an injectable out of the cells of cadavers may sound macabre, but there are plenty lining up to spend tens of thousands for a jab of this 'game-changing' substanceBoard-certified plastic surgeon Dr Darren Smith told the Daily Mail: 'Essentially, it functions as an off-the-shelf fat graft, a way to give someone volume in a place they don't have it.'And, in the age of mass GLP-1 use, that aesthetic concern is certainly front of mind.'When you lose weight and you get to your goal weight, that's amazing. At the same time, you might lose volume along the way from places you don't want,' the New York City-based surgeon said. Indeed, GLP-1 users comprise a considerable portion of his patient population.Fat grafting is an obvious solution for targeting specific areas of volume loss following a dramatic drop in weight.But equally obvious is the problem that, once that weight has been shed, the patient has little body fat available for the procedure. Hence the hunt for a viable alternative.Until now, for patients not wanting implants, 'fat banking' – the process of removing fat with liposuction then storing it in a freezer to save for an injection, weeks, months or years later – has seemed the only option.Fat transfers can cost anywhere from $5,000 to $10,000, and storage is around $1,500 to $2,000 for the first year and additional monthly fees after that.But it's unclear just how long that kind of fat can be safely stored and many doctors have warned against it.'Fat banking does not work because fat is not survivable in the fridge or freezer. The fat will die,' Dr Andrew Cohen, a board-certified plastic surgeon in California, told the Daily Mail.'I have been in practice over 25 years and as a board-certified plastic surgeon, I don't know any of my mentors or esteemed colleagues who actually banks fat.'So where does that leave GLP-1 users desperate to get rid of the drug's hallmark 'deflated' look?'Until six or seven months ago, we were kind of scratching our heads,' Smith said.Not anymore. Cue, the somewhat ghoulish, Alloclae.Derived from 'cadaveric adipose tissue' – otherwise known as the fat of dead people – Alloclae hit the market last year after a decade in development.The tissue is stripped of all its genetic materials, leaving only the three-dimensional honeycomb cell membrane architecture of fat cells.This process prevents the recipient from rejecting the filler as a foreign body while allowing it to retain cell structure.The presence of this cellular blueprint means that, when injected into the target area via a tiny incision, the patient's stem cells infiltrate the scaffolding created by Alloclae and the connective tissue eventually integrates with the patient's.Within six months, it is impossible to decipher what was Alloclae and what is the patient's own tissue.Caro Van Hove, the president of Tiger Aesthetics Medical, a division of Tiger BioSciences, told the Daily Mail, 'When you look at the world of healthcare, medicine, the market is really evolving towards materials that are more harmonious with the body.' 'The market is really evolving towards materials that are more harmonious with the body,' Caro Van Hove, the president of Tiger Aesthetics Medical, a division of Tiger BioSciences, told the Daily MailIt is a marked shift away from synthetic materials and, as she put it, towards focusing on how to 'leverage the body's own material and make it work better.'The procedure takes 30 to 60 minutes and the most common areas of concern are the breasts, buttocks and those 'hip dips.' It can also be used to correct previously botched liposuction.While the thought of receiving donor tissue from the deceased might make your skin crawl, surgeons insist that Alloclae is a new frontier in aesthetics – a solution to a previously 'unmet need,' board-certified plastic surgeon Dr Sachin Shridharani told the Daily Mail.In a single day, he sees three or four new patient consults for Alloclae, including those who live overseas and are considering traveling to the US – the only country where the Food and Drug Administration (FDA) approved product is available – for the procedure.On average, he estimates he sees ten new patient consults for Alloclae a week, with a large number of those going through with the injection.Those numbers are unprecedented, according to the New York City surgeon.'You're not seeing ten new patient facelift consults a week and ten new patient breast augmentation consults a week,' he said. 'For ten or 15 [people] to come in and be like 'I want Alloclae,' that says something to us about the significant amount of interest and excitement.'Its popularity, he said, has only been growing over the past year since he started offering Alloclae to patients, regardless of its price tag.Alloclae is considerably costly, coming in at an estimated $30,000 at Smith's office for a natural-looking breast augmentation. However, it's still cheaper than a typical Brazilian Butt Lift or breast implant.It's also more bang for your buck in the long run.Smith, who started offering Alloclae in the latter half of 2025, said the results are more permanent than those of traditional fat grafting.For instance, in using the patient's own fat, he said, 'If you get a fat graft from, say, your abdomen to your face, and then you gain weight in your abdomen, you now gain weight in your face.' That's because the transferred fat still behaves like abdominal fat, despite now living in the face.With Alloclae, that should not happen if the patient gains weight. 'It will be a lot more consistent,' he said.But can production keep up with the demand?'There is a limited supply,' Shridharani said. 'Ultimately you are injecting a tissue product that has been gifted in kind by a human that was willing to donate their body to science, so to speak. So, it's not like you can just manufacture an unlimited amount of it by opening ten different factories.'But according to Van Hove, Tiger Bioscience's heritage as a leader in this field ensures the company will be able to keep pace with the rampant patient demand. An athletic BBL that was done with AlloClae Board–certified plastic surgeon Dr Darren Smith told the Daily Mail: 'Essentially, it functions as an off–the–shelf fat graft, a way to give someone volume in a place they don't have it.' These image shows a patient of Dr Smith before (left) and after (right) receiving AlloClae for a mini BBLThe process by which Alloclae is manufactured is tightly regulated by the FDA. Tiger Biosciences, she added, only works with tissue banks accredited by the American Association of Tissue Banks and screens every donor, and five years' worth of their medical history, to rule out transmissible diseases and other risk factors.Consent from the donor is, of course, required. According to Van Hove, donors can choose how their organs are to be used after their death, whether it is for medical purposes only or just for clinical research. No explicit products, however, are listed on the form.Of course, like any procedure, there are risks and possibility of complications such as cystic nodule formation, pain, infection at the incision site, hematoma, allergy or immune responses and discoloration of the skin, she added.But for many, results outweigh the risk.Stacy, 35, who declined to provide her last name, received her first Alloclae injection last July at Smith's office after a botched fat transfer from her thigh a few years ago, which left her 'traumatized.''I've tried everything. I spent so much money trying to figure anything out to fix it,' the New Yorker told the Daily Mail. 'I was really skeptical about Alloclae, but I did it and it fixed it. Like, I look like a normal human again.'Her slender frame did not make her a viable candidate for a fat graft using her own fat, so she received two Alloclae injections in her inner left thigh and three to address her 'hip dips' and achieve a 'mini BBL' that she said looks incredibly natural.'I can wear different clothes now,' she said. 'I haven't worn shorts, I hadn't worn skirts in years because of these issues and now I could comfortably do it.'And though some doctors might knock emerging procedures like 'fat banking' as merely 'fads,' it seems unlikely that the Alloclae buzz will fade anytime soon.As Stacy put it: 'It has changed my life.'
